Shares of Cipla and Strides Arcolab gained on Thursday after collaborating with Medicines for Malaria Venture (MMV). MMV signed collaboration agreements with Cipla and Strides Arcolab for the development of rectal artesunate for pre-referral treatment of children with severe malaria.

The collaborations, established under the MMV-led 'Improving Severe Malaria Outcomes' project funded by UNITAID1, aim to develop a rectal artesunate product for submission to WHO prequalification.

Shares of Cipla gained Rs 7.65, or 1.22%, to trade at  Rs 636.  The total volume of shares traded  was  212,024 at the BSE.

Meanwhile, share of Strides Arcolab rallied Rs 50.1, or 6.82%, to trade at  Rs 785.  The total volume of shares traded  was 189,815 at the BSE (3.14 p.m., Thursday).